GSK Applauds U.K.'s Tax Changes, Announces New Jobs And Manufacturing Facilities
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline is to invest £500 million in new U.K. manufacturing facilities in Ulverston, Montrose and Irvine, creating 1,000 jobs in the process.
You may also be interested in...
Patent Incentives Pitched As Part Of Corporate Tax Reform
European-style 'patent box' recommended by former Allergan CEO at Senate hearing.
European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box
EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.
Pfizer/AstraZeneca: Battleground Shifts To U.K. Parliament
Pfizer CEO Read tried to assure U.K. legislators that an acquisition of the country’s second-largest drug company would not stunt pharma R&D in Britain at a May 13hearing. AstraZeneca CEO Soriot countered that the company’s pipeline will progress quicker if the company remains independent, resulting in future benefits to the U.K.